Navigation Links
Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Date:9/4/2007

("SCIT"). Antigen provides allergenic extracts to over 1,500 physicians in the United States annually.

"We are excited to work with the Planet team to develop substantial growth opportunities for immunotherapy in the U.S.", said Tom Willoughby, President at Antigen. Mr. Willoughby will continue as president of Antigen, as well as become Vice-Chairman of Planet's Board of Directors.

Planet believes that the base businesses of both ACP and Antigen will benefit from cross merchandising between each company's physician relationships. As such, the acquisition of Antigen is part of Planet's overall goal to build a specialty pharmaceutical company focused on asthma and allergy, implementing consolidation and cross merchandising activities within the allergy market.

Importantly, upon completion of the acquisition, the company intends to commence a sublingual immunotherapy ("SLIT") clinical development program. SLIT is the administration of immunotherapy through drops of allergenic extract being placed under the tongue, versus the traditional SCIT route of administration. It is a particularly attractive treatment alternative for young children, those at increased risk for SCIT (i.e. asthmatic persons), and those who cannot go to a physician's office once a week for an injection.

In European countries where SLIT has received regulatory approval, it has been reported that the availability of both SCIT and SLIT has greatly expanded the number of patients seeking immunotherapy. The company believes that an FDA-approved SLIT product also will expand the much larger U.S. market, as allergy-related physicians will have the enhanced option of offering either SCIT or SLIT based immunotherapy for their patients.

There are six competitors in the allergenic extract immunotherapy market within the U.S,

In addition to the $10 million acquisition price, Planet estimates it will need $10 million for transaction-related professional fees, payoff of debts,
'/>"/>

SOURCE Planet Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Global Polio Eradication: A Campaign to Vaccinate Every Child on the Planet
2. Protecting Oceans is Important to Keeping Planet Cool
3. New green Pyre to Cool Planet While Burning Indias Dead
4. Work Less to Sustain Planet Earth, Say Activists
5. Worms are Killing the Planet
6. Researchers Develop Technologies to Devour Food Pathogens
7. Researchers Study Safety of Assisted Reproductive Technologies
8. India to Propose Global Fund for Clean Energy Technologies
9. PM announces a new health care order for India
10. PowderMed Announces Needle-Less Flu Vaccine
11. Ramdoss Announces Introduction of RCH-II
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Eye Surgery Errors Rare But Serious 2Health News:Wal-Mart Foundation Announces $1 Million Grant to the Meharry Medical College Center for Women's Health Research 2Health News:Wal-Mart Foundation Announces $1 Million Grant to the Meharry Medical College Center for Women's Health Research 3Health News:Wal-Mart Foundation Announces $1 Million Grant to the Meharry Medical College Center for Women's Health Research 4Health News:Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:AMA Commends Aetna for Quality First Commitment 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 3Health News:Higher-risk kidneys may help solve organ shortage facing older adults 2Health News:Higher-risk kidneys may help solve organ shortage facing older adults 3
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 1B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 2B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 3B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 4The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 49748 1The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 49748 2The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 49748 3Pennsylvania Department of Health Receives Recovery Funds for New Healthy Homes Program 49746 1Pennsylvania Department of Health Receives Recovery Funds for New Healthy Homes Program 49746 2